Company Name
Cellatope

Web Site
www.cellatope.com

Description of Company Mission
Cellatope Corporation (formerly StageMark) is developing a novel and proprietary biomarker panel related to the complement activation pathway (CB-CAPs/Cell-Bound Complement Activation Products) for the diagnosis and more importantly the monitoring of challenging auto-immune diseases such as lupus. This technology was in-licensed from the University of Pittsburgh.

Industry
Diagnostics

Stage of Commercialization
Seed

Market Size
$200M

PLSG Funding to Date
$90,000

CEO Name
Edward L. Erickson

PLSG Executive in Residence
H. Safferstein

Number of Employees
2

Location
Philadelphia, PA